The Convergence Discovery Research: identification and exploitation of cancer vulnerabilities theme focuses on enhancing our understanding of cancer biology and translating this into patient benefit through transformative, proof-of-concept, investigator-initiated clinical trials. 


The primary focus of this theme is to support collaborative endeavours that develop new tools and technologies to address currently intractable problems in cancer biology, and to integrate these innovation within a translational pipeline, whenever possible. Closely supported by our Clinical Drug Development and Data Science initiatives, we aim to create iterative and reverse translational collaborations, allowing clinical trial materials (e.g, patient data, liquid and solid biopsies) to guide Discovery Research to, in return, inform future clinical trials. Compelling problems we wish to address include outstanding questions around cancer emergence, adaptation, response to treatment, resistance, metastasis and recurrence. The Convergence Science Centre strongly support the development of 3D patient-derived cancer models – including organoids, co-culture systems, organ on a chip and explant cultures. Our ambition is to engage engineering, mathematics and physical science (EPS) research groups to utilise the extraordinary potential of patient-derived models to solve unanswered biological questions, and find solutions to unmet clinical needs.


If you have any questions relating to the Multidisciplinary Discovery Research theme please contact Arnaud Legrand  ( /